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Abstract
Introduction Typical medullary breast carcinoma (MBC) has
recently been recognized to be part of the basal-like carcinoma
spectrum, a feature in agreement with the high rate of TP53
mutations previously reported in MBCs. The present study was
therefore designed to identify phenotypic and genetic
alterations that distinguish MBCs from basal-like carcinomas
(BLC).
Methods Expression levels of estrogen receptor (ER),
progesterone receptor (PR), ERBB2, TP53, cytokeratins (KRTs)
5/6, 14, 8/18, epidermal growth factor receptor and KIT, as well
as TP53 gene sequence and high-density array comparative
genomic hybridization (CGH) profiles, were assessed and
compared in a series of 33 MBCs and 26 BLCs.
Results All tumors were negative for ER, PR and ERBB2. KRTs
5/6 were more frequently expressed in MBCs (94%) than in
BLCs (56%) (p = 0.0004). TP53 mutations were disclosed in
20/26 MBCs (77%) and 20/24 BLCs (83%). Array CGH
analysis showed that a higher number of gains (95 regions) and
losses (34 regions) was observed in MBCs than in BLCs (36
regions of gain; 13 regions of losses). In addition, gains of 1q
and 8q, and losses of X were found to be common to the two
groups, whereas gains of 10p (53% of the cases), 9p (30.8% of
the cases) and 16q (25.8% of the cases), and losses of 4p
(34.8% of the cases), and amplicons of 1q, 8p, 10p and 12p
were the genetic alterations found to characterize MBC.
Conclusion Our study has revealed that MBCs are part of the
basal-like group and share common genomic alterations with
BLCs, the most frequent being 1q and 8q gains and X losses;
however, MBCs are a distinct entity within the basal-like
spectrum, characterized by a higher rate of KRT 5/6 expression,
a higher rate of gains and losses than BLCs, recurrent 10p, 9p
and 16q gains, 4p losses, and 1q, 8p, 10p and 12p amplicons.
Our results thus contribute to a better understanding of the
heterogeneity in basal-like breast tumors and provide potential
diagnostic tools.
aCGH = array comparative genomic hybridization; BAC = bacterial artificial chromosome; BLC = basal-like carcinoma; ER = estrogen receptor; FISH 
= fluorescence in situ hybridization; KRT = cytokeratin; MBC = medullary breast carcinoma; PAC = P1-derived artificial chromosome; PR = proges-
terone receptor; SSC = standard saline citrate.Breast Cancer Research    Vol 9 No 2    Vincent-Salomon et al.
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Introduction
Medullary breast carcinomas (MBCs) represent 2% of all inva-
sive breast carcinomas, and although these tumors show
aggressive pathological features they are often associated
with a more favorable outcome. They are defined by an asso-
ciation of five morphological features [1]: a predominantly syn-
cytial growth pattern, a circumscribed border, a moderate to
marked lymphoplasmacytic infiltrate, poorly differentiated
nuclear grade with high mitotic rate, and the absence of glan-
dular features or any in situ component. Despite these defined
morphological features, reproducibility of diagnosis is only
moderate. Therefore, more specific and new diagnostic crite-
ria such as genetic features would be very helpful. Gene
expression profile analysis classifies breast carcinomas into
five groups: luminal–epithelial/estrogen receptor (ER)-positive
A and B, basal-like, ERBB2, and normal-like carcinomas [2-5].
The basal-like group of tumors was associated with a poorer
outcome than that of luminal tumors [5]. Moreover, basal-like
carcinomas (BLCs) were characterized by a specific immu-
nophenotype that was negative for ER, progesterone receptor
(PR) and ERBB2, and positive for cytokeratin (KRT) type 5/6,
KRT 14 or KRT 17, epidermal growth factor receptor (EGFR)
and KIT; [5,6] they were also associated with TP53 mutations
[3]. We have previously shown that MBCs were associated
with a very high rate of TP53 mutations [7]. Recently MBCs
were found to present a basal-like/myoepithelial phenotype
[8,9] with a specific gene overexpression profile [10]. We and
others have demonstrated that MBCs have a favorable out-
come despite the aggressive pathological features at presen-
tation [11-13] and unlike basal-like tumors [5]. This favorable
outcome may be explained in part by the radiosensitivity and
chemosensitivity of MBCs [11]. To address the biological dif-
ferences between MBCs and BLCs, we performed an immu-
nophenotype analysis, a TP53 sequence analysis and large-
scale analysis by array comparative genomic hybridization
(aCGH) on a series of 33 MBCs and compared their immuno-
profiles and genetic alterations with those of a group of 26
non-medullary BLCs. These analyses reveal that MBCs have
distinct specificities, both at the immunophenotypic level,
including more frequent cytokeratin 5/6 expression, and at the
genomic level with a high level of chromosome gains and
losses, recurrent 10p, 9p and 16q gains and 4p losses, and
1q, 8q, 10p and 12p amplicons.
Materials and methods
Patients and tumors
We studied tumors from two groups of patients. Experiments
were performed in accordance with Bioethics Law no. 2004-
800 and the Ethics Charter from the National Institute of Can-
cer (INCa). The first group consisted of 33 MBCs; the second
group consisted of 26 non-medullary BLCs.
We initially selected 42 patients with MBCs from our files, pro-
spectively registered in our institutions (32 cases from Institut
Curie and 10 cases from Institut Bergonié) for which a repre-
sentative paraffin-block sample and a frozen sample were both
available. Samples with less than 50% of tumor cells were
excluded from the study. A retrospective pathological review
of all cases was performed by four breast pathologists (AVS,
BSZ, GMG and IdM) in accordance with Ridolfi's criteria [1],
namely pushing margins, syncytial growth pattern without any
glandular structures, high nuclear grade with a vesicular chro-
matin and a high mitotic activity, a dense lymphoplasmacytic
infiltrate and no associated ductal carcinoma in situ. We have
considered here that the three major morphological traits that
most clearly distinguish MBCs from BLCs were as follows:
first, the presence of large nuclei, irregular in shape, with vesic-
ular chromatin and large eosinophilic nucleoli; second, cells
organized in solid syncytial sheets seven to eight cells thick, in
a ribbon-like structure; and third, the interspersing of the rib-
bon-like structure with a stroma composed of a dense lympho-
plasmacytic infiltrate with no myofibroblasts and no fibrosis.
Seven cases were excluded after pathological review and two
for insufficient aCGH quality (see Additional file 1); 33
patients with MBCs were eventually available for genetic
analysis.
The second group of tumors were from 26 patients with BLCs.
These cases were selected from our files among ER- PR-
ERBB2- invasive ductal carcinomas, according to their basal
immunophenotype, defined as follows: ER- PR- ERBB2- with
the expression of at least one of the following markers: basal-
myoepithelial KRT 5/6, KRT14, EGFR and KIT.
DNA and RNA extraction
DNA was extracted from frozen tumor samples with the use of
a standard phenol/chloroform procedure. A frozen tissue sec-
tion was performed on the remaining frozen fragments to eval-
uate tumor cellularity. All tumors analyzed presented more than
50% of tumor cells on the control tissue section. Total RNA
was extracted from frozen tumor samples with the RNeasy® kit
(Qiagen, Courtaboeuf, France), then the RNA clean up kit
(Macherey Nagel, France), in accordance with the manufactur-
ers' instructions. The quality of each RNA sample was meas-
ured with an Agilent 2100 bioanalyzer. The quantity of RNA
was measured by spectrophotometry at 260 nm.
Immunohistochemistry
Immunostaining was performed on 4 μm tissue sections pre-
pared from a representative sample of the tumor. After rehy-
dration and antigenic retrieval in citrate buffer (10 mM, pH
6.1), tissue sections were stained for ER (clone 6F11, 1/200
dilution; Novocastra, Newcastle Upon Tyne, UK), PR (clone
1A6, 1/200 dilution; Novocastra), ERBB2 (clone CB11, 1/
1,000 dilution; Novocastra), EGFR (HER1; clone 31G7, 1/40
dilution; Zymed), CD117 (an epitope of KIT, polyclonal, 1/100
dilution; Dako A/S, Glostrup, Denmark), TP53 (clone DO7, 1/
50 dilution; Dako), KRT 5/6 (clone D5/16B4, 1/50 dilution;
Dako), KRT 8/18 (clone DC10, 1/100 dilution; Zymed) and
KRT 14 (clone LL002, prediluted; Biogenex, San Ramon, CA,Available online http://breast-cancer-research.com/content/9/2/R24
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USA). Staining was conducted with the Vectastain Elite ABC
peroxidase mouse IgG kit (Vector Laboratories, Burlingame,
CA, USA), with diaminobenzidine (Dako) as the chromogen.
Positive nuclear staining for ER, PR and TP53 was recorded
in accordance with standardized guidelines, using 10% of
positive cells as the cutoff for ER, PR and TP53. For ERBB2,
only staining of membranes was considered, as defined previ-
ously [14,15]. CD117 and KRT 5/6, KRT 14 and KRT 8/18
were scored positive if any (weak or strong) cytoplasmic and/
or membranous invasive carcinoma cell staining was observed
in accordance with previous published studies [6,8,16,17].
For EGFR, 10% of positive membranous staining was used as
the positive cutoff. For each antibody, internal and external
controls were included in the experiments.
TP53 sequencing
TP53 was sequenced in accordance with the previously pub-
lished procedure [7] or directly from DNA. The TP53
sequence was not assessed for nine cases for which no more
RNA or DNA was available after aCGH. In brief, for sequenc-
ing from RNA, total RNA was reverse-transcribed in a final vol-
ume of 20 μl containing 1× reverse transcriptase buffer, 10
units of RNase inhibitor (Promega, Madison, WI, USA), 10 mM
dithiothreitol, 50 units of Superscript II RNase H reverse tran-
scriptase (Life Technology, Inc., Cergy Pontoise, France), 1.5
mM random hexamers (Pharmacia, Uppsala, Sweden) and 1
μg of total RNA. Samples were incubated at 20°C for 10 min-
utes and at 42°C for 30 minutes; reverse transcriptase was
then inactivated by heating at 99°C for 5 minutes and cooling
for 5 minutes. For sequencing from DNA, total DNA was ampli-
fied with primers specific for exons 4 to 10 (primer sequences
are listed in Additional file 1). Purified PCR products were
sequenced bidirectionally with the use of Big Dye Terminator
chemistry (Applied Biosystems, Foster City, CA, USA) with an
ABI Prism 3700 DNA Analyzer (Applied Biosystems, Foster
City, CA, USA). The central part of the TP53 gene (amplified
from cDNA between exons 4 and 10, namely codons 42 to
374) was sequenced for all samples.
Array CGH
The array used contains 3,261 bacterial artificial chromosome
(BAC) and P1-derived artificial chromosome (PAC) DNAs, as
described previously [18]. All BACs and PACs were verified
by end sequencing before spotting, and their positions on the
genome have been determined. In brief, after digestion with
DpnII (Ozyme, Saint Quentin en Yvelines, France) and column
purification (Qiagen PCR Purification Kit; Qiagen), 1.5 μg of
tumor DNA and 1.5 μg of normal male DNA were labeled
using the BioPrime DNA Labeling System Kit (Invitrogen,
Cergy-Pontoise, France), with Cy5dCTP or Cy3-dCTP (Amer-
sham, Uppsala, Sweden), respectively. Labeled tumor and ref-
erence DNAs were mixed and precipitated together with 225
μg of human Cot-1 DNA (Invitrogen), resuspended in 65 μl of
hybridization buffer (50% formamide, 40 mM NaH2PO4, 0.1%
SDS, 10% dextran sulfate, 2 × standard saline citrate (SSC),
Denhardt's solution), denatured, prehybridized for 90 minutes
at 37°C and hybridized on treated microarray slides. After 24
hours of hybridization at 37°C in a humidity chamber and
appropriate washing, slides were scanned with a GenePix
4000B scanner (Axon Instruments Inc., Union City, CA, USA)
and analyzed with GenePix Pro 5.1 image analysis software,
which defined the spots and determined the median intensi-
ties for the Cy3 and Cy5 signals of each BAC clone.
Analysis of aCGH data
Data analysis was based on the normalized ratios of Cy5/Cy3
signals observed for each BAC clone [19] that previously
passed the flag assessment procedure (see Additional file 2).
For autosomal chromosomes, the loss of a given locus was
defined by a ratio less than or equal to 0.8, a gain was defined
by a ratio greater than or equal to 1.2 and less than 2.0, and
an amplicon was defined by a ratio greater than or equal to 2.0.
For X chromosomes, a loss was defined by a ratio less than or
equal to 1.2, a gain was defined by a ratio greater than or equal
to 1.7, and an amplicon was defined by a ratio greater than or
equal to 2.5. Whenever a statistical hypothesis concerning the
levels of the ratios was tested, the hypothesis was considered
to be rejected for p values less than or equal to 0.05. When-
ever p values were adjusted for multiple hypothesis testing, the
false discovery rate using the Benjamini–Hochberg procedure
was applied (R-Multitest package).
Data analysis was performed with two complementary
approaches: a descriptive approach and a statistical
approach. For the descriptive approach, the frequency of BAC
locus gains, losses and amplicons in the two groups of tumors
was evaluated to identify genomic regions that could distin-
guish MBC tumors from BLC tumors. For a given tumor, a
region of gain or loss was defined as a set of at least two con-
secutive BAC loci meeting the gain and loss criteria described
above. A region of gain or loss was considered as recurrent
when it was observed in at least 20% of tumors. The median
frequency was calculated for each region defined previously,
to determine the most recurrent alterations. The regions of
gains and losses were compared between the two groups by
a Fisher exact test, BAC locus by BAC locus (p values were
not adjusted for multiple tests). A region was considered to be
significantly different between the two groups when the major-
ity of the loci in the region presented p values less than 0.05.
For analysis of amplicons, the identification criteria were BAC
loci consisting of at least one clone with a ratio greater than or
equal to 2.0 in one tumor. Finally, a between-group compari-
son of the mean ratios of each BAC loci in the two groups of
tumors was performed; ratios were log2 transformed, the nor-
mal distribution of ratios in the two groups was tested by the
Shapiro–France test (R-Nortest package), comparisons were
performed with a Welch T test and the hypothesis of no differ-
ence between the two groups was rejected when theBreast Cancer Research    Vol 9 No 2    Vincent-Salomon et al.
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Benjamini–Hochberg false discovery rate, calculated over the
3,264 BAC loci analyzed, was less than or equal to 5%.
For the unsupervised statistical approach, hierarchical cluster-
ing was performed to define tumor groups with no a priori bio-
logical knowledge (see Additional file 3). Its robustness was
tested by a resampling approach (see Additional file 3). The
enrichment of the groups in BLC and MBC tumors was then
tested (Welch T test), and genomic regions able to discrimi-
nate between the two groups were determined.
Fluorescence in situ hybridization (FISH) experiments
To verify the most recurrent gains observed on the aCGH
results, FISH analysis was performed on representative frozen
samples of four MBCs that demonstrated 10p gains on
aCGH, and four BLCs without 10p gains. Frozen tissue sec-
tions 4 μm thick were prepared and fixed for 10 minutes in a
mixture of ethanol/acetic acid (2:1, by volume). A probe was
selected within the regions of gains on the 10p chromosome
that differentiated MBC from BLC clusters (TelVysion Spec-
trum Green 10p from Vysis-chr10: 328,262 to 328,575, and
BAC clone g1int953-chr10: 22,497,751 to 22,668,197) and
a BAC clone associated with a normal ratio in every case
(g1int978-chr10: 50,248,127 to 50,413,107) as control. The
BAC DNAs were extracted in accordance with standard pro-
cedures. The DNAs were then labeled by nick translation
using the BioNick Labeling Kit (BioNick Labeling System; Inv-
itrogen) and the following fluorescent nucleotides: Texas red-
dUTP (NEN, Paris, France) for g1int953, and Cy3-dUTP
(Amersham, Orsay, France) for g1int978. Each 10p probe
was pooled and co-precipitated with the control probe and
with an excess of human Cot1 DNA. Denaturation of the
probes was performed at 94°C for 10 minutes; the tissue sec-
tions were denatured in formamide and 2 × SSC at 72°C for
2 minutes. The probes were then hybridized on the tissue sec-
tion under a coverslip. Slides were incubated overnight at
37°C in humid chambers, then washed briefly in 1 × SSC for
5 minutes at 20°C and for 5 minutes at 72°C. Finally, slides
were counterstained with 4,6-diamidino-2-phenylindole (Vec-
tor Laboratories). Images were captured with an Axioplan 2
microscope (Zeiss, Le Pecq, France) with appropriate filters
and a Quantix camera (Photometrics, Tucson, AZ, USA) using
SmartCapture software (Digital Scientific, Cambridge, UK).
Images of an average of 30 nuclei per case were taken and the
number of signals for each probe was counted. The mean
number of copies of each locus was then determined and
compared with the control locus.
Results
Clinical characteristics of patients
Because several studies have shown a higher incidence of
MBCs in young patients, in particular in a BRCA1 context, we
compared the ages of the two groups of patients (MBC group:
median 53.5 years; range 34 to 76 years; BLC group: median
60 years; range 37 to 82 years; Table 1). The age tended to
be younger in MBCs, but the difference was not significant (p
= 0.072, Wilcoxon rank test). Other clinical characteristics
were also noted. The clinical stage was T1 for 14 patients with
MBC and 6 with BLC, T2 for 15 patients with MBC and 19
with BLC, T3 for 2 patients with MBC and 1 with BLC, N0 for
24 patients with MBC and 18 with BLC, and N1 for 7 patients
with MBC and 8 with BLC (clinical stage was not determined
for 2 patients with MBC). All MBCs were of grade III; in com-
parison, 19 BLCs were of grade III and seven were of grade II
(p = 0.0056, χ2 test).
TP53 mutations
We have previously reported that TP53  mutations were a
genetic trait of MBCs [7], and a high rate of such mutations
has been found in BLCs [3]. We therefore assessed the TP53
sequences in 26 of the 33 MBCs and 24 of the 26 BLCs
(Table 1). A mutation in TP53 was found in 20 of the 26 MBCs
(77%); 16 of these were associated with intense TP53 immu-
nolabeling of tumor cell nuclei (16/20 mutations; Table 2).
There was a TP53 mutation in 20 of the 24 BLCs sequenced
(83%), including five of the seven grade II tumors. In the BLCs,
TP53 immunolabeling was concordant with TP53  mutation
status in all cases (100% of mutated cases). No significant dif-
ference in TP53 status was observed between MBCs and
BLCs (p > 0.05).
Comparative immunophenotypes of MBCs and BLCs
To address the question of whether MBCs and BLCs present
any immunophenotypic difference, we analysed the status of
markers that contribute to the definition of a basal-like immu-
nophenotype, namely ER, PR, ERBB2, KRT 5/6, KRT 14 and
KRT 8/18 in the two groups (Table 2). We observed that all
tumors from the MBCs group and the selected BLCs tumors
were negative for ER, PR and ERBB2. However, a comparison
of the immunophenotype of the two groups of tumors showed
that MBCs were more often positive for KRT5/6 than BLCs
(30/32 (94%) versus 14/25 (56%), respectively; p = 0.0007).
No difference in immunophenotype was observed between
MBCs and BLCs for KRT14 (17/31 (55%) versus 18/23
(78%); not significant), TP53 (20/33 (61%) versus 12/25
(48%); not significant), KRT 8/18 (30/32 (94%) versus 19/25
(76%); not significant), EGFR (22/32 (69%) versus 10/22
(45%); not significant) or KIT (19/32 (59%) versus 12/20
(60%); not significant).
Array CGH results
To our knowledge, no unique, standardized method for the
analysis of aCGH data has yet been published. We therefore
decided to analyse our data with two different approaches: the
in the first we looked for the regions already known to be
amplified in breast carcinogenesis and described the other
new ones. We also evaluated the frequency of gains and
losses in the two groups. As a second approach, we used
unsupervised clustering. The outcomes of these two
approaches led us to draw the same conclusions, which sug-Available online http://breast-cancer-research.com/content/9/2/R24
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Table 1
Clinical and biological characteristics of patients with MBCs and BLCs
Case no. Age (years) TNM stage Histoprognostic grade TP53 status
BLC
16 9 T 2 N 0 3 e x 7 G →A/p. Arg 248 Gln
26 6 T 1 N 0 2 e x 5 G →T/p. Cys 176 Phe
36 0 T 2 N 0 2 e x 8 G →A/p. Asp 281 Asn
46 4 T 2 N 0 2 i n t 6 S p l i c e
55 1 T 2 N 1 a 3 w t -
66 2 T 1 N 1 a 2 w t -
77 0 T 1 N 0 3 e x 7 G →A/p. Gly 245 Ser
83 7 T 1 N 0 2 e x 6 C →T/p. Arg 213 STOP
96 2 T 2 N 0 2 e x 6 T →G/p. Ser 215 Arg
10 60 T2N1b 3 ex8 C→T/p. Arg 282 Trp
11 52 T2N1 3 ex6 C→T/p. Arg 213 STOP
12 50 T3N1 3 ex5 G→A/p. Arg 175 His
13 79 T2N0 3 ex5 C→T/p. Ala 159 Val
14 48 T2N0 3 ex10 Del codon 333
15 42 T1N0 3 ex6 Del codon 196
16 52 T2N1b 2 wt -
17 82 T2N0 3 wt -
18 46 T2N1a 3 nd -
19 51 T2N0 3 nd -
20 81 T2N0 3 ex7 A→G/p. Tyr 236 Cys
21 n.d. T2N0 3 ex6 T→C/p. Ile 195 Thr
22 40 T1cN0 3 ex6 T→G/p. Leu 194 Arg
23 69 T2N0 3 ex5 G→A/p. Arg 175 His
24 69 T2N0 3 ex5 C→A/p. Tyr 126 STOP
25 55 T2N0 3 ex6 C→T/p. Arg 213 STOP
26 77 T2N1 3 ex7 A→C/p. Thr 253 Pro
MBC
1 46 T1cN1 3 ex7 Del codon 241
2 34 nd 3 ex7 Del codon 252
34 6 T 2 N 0 3 e x 5 G →A/p. Arg 175 HisBreast Cancer Research    Vol 9 No 2    Vincent-Salomon et al.
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47 2 T 1 c N 0 3 e x 8 G →A/p. Arg 280 Lys
53 9 T 3 N 1 3 w t -
65 3 T 2 N 0 3 n d -
74 9 T 1 c N 0 3 n d -
84 9 T 1 c N 0 3 n d -
93 3 T 2 N 0 3 n d -
10 63 T2N0 3 nd -
11 66 T2N0 3 nd -
12 50 T1cN1a 3 nd -
13 57 T1cN0 3 ex7 G→A/p. Arg 248 Gln
14 68 T2N0 3 ex6 C→T/p. Arg 213 STOP
15 61 T2N0 3 ex6 A→G/p. Tyr 220 Cys
16 56 T2N0 3 wt -
17 58 T2N0 3 ex8 G→A/p. Glu 286 Lys
18 57 T2N0 3 ex8 G→A/p. Cys 275 Tyr
19 62 T2N0 3 ex7 G→A/p. Arg 248 Gln
20 35 T1cN0 3 ex6 A→G/p. His 193 Arg
21 54 T1cN1 3 ex7 G→A/p. Cys 242 Tyr
22 36 T2N1 3 wt -
23 48 T1cN1 3 ex6 Ins codon 213
24 56 T1cN0 3 ex5 C→A/p. Ala 161 Asp
25 42 T3N0 3 ex6 G→A/p. Val 216 Met
26 43 T2N0 3 ex10 G→T/p.Glu 339 STOP
27 66 T1cN0 3 ex5 Ins codon 125
28 50 T1cN0 3 ex5 G→A/p. Arg 175 His
29 41 T2N0 3 ex5 T→C/p. Ser 127 Pro
30 n.d. n.d. 3 ex6 A→G/p. Tyr 220 Cys
31 76 T2N0 3 wt -
32 72 T1cN1 3 wt -
33 67 T1cN0 3 wt -
BLC, basal-like carcinoma; MBC, medullary breast carcinoma; n.d., not determined; wt, wild type; del, deletion; ins, insertion; int, intron; ex, exon; 
p, protein.
Table 1 (Continued)
Clinical and biological characteristics of patients with MBCs and BLCsAvailable online http://breast-cancer-research.com/content/9/2/R24
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gest that the new BLC entity could gather different genomic
subgroups, one being MBC.
The genes most frequently involved in breast carcinogenesis
(MYC, CCND1, EGFR and CCNE) were very rarely found
amplified in the two groups.
In 17 different MBCs (51%), 59 different amplicons, observed
in at least one tumor, were found; in 9 different BLCs (35%),
39 different amplicons were observed. Recurrent amplicons
were rare (Table 3; see also Additional file 4).
Amplicons located on chromosomes 1q, 8p, 10p and 12p
were within the most frequent regions of gains and were never
observed in BLCs. Only amplicons in 8q24, encompassing
MYC, and in Xq28 were observed in both groups.
The complete list of regions of gains and losses (frequency
greater than 20%) in MBCs and BLCs is presented in Addi-
tional file 5. The discriminative regions of gains and losses in
MBCs and BLCs are listed in Table 4, and an average of the
genomic profiles of BLCs and MBCs are presented in Figure
1.
As shown in Table 4, very discriminative regions of gains were
observed on chromosomes 3, 9, 10, and 16 in the MBCs. The
highest frequencies of gain were observed at 10p13 (53%) (p
= 0.018). A discriminative region of loss was observed on
chromosome 4p15.2 (34.8%) (p = 0.025).
BLCs were associated with fewer rearrangements than MBCs
(see Additional file 5). One discriminative region of loss was
observed on the X chromosome in BLCs, with a median fre-
quency of 38.5% of cases (p = 0.001).
Table 2
Immunophenotypes of basal-like carcinomas and medullary breast carcinomas
Marker Medullary breast carcinomas (n = 33) Basal-like carcinomas (n = 26) p
ER + 0 (0) 0 (0)
- 33(100) 26 (100) -
PR + 0 (0) 0 (0)
- 33(100) 26 (100) -
ERBB2 + 0 (0) 0 (0)
- 32 (100) 25 (100) -
n.d. 1 1
TP 53 + 20 (61) 12 (48)
- 13 (39) 13 (52) n.s.
n.d. 0 1
KRT 5/6 + 30 (94) 14 (56)
- 2 (6) 11 (44) 0.0004
n.d. 1 1
KRT 8/18 + 30 (94) 19 (76)
- 2 (6) 6 (24) 0.06
n.d. 1 1
KRT 14 + 17 (55) 18 (78)
- 14 (45) 5 (22) n.s.
n.d. 2 3
EGFR + 22 (69) 10 (45)
- 10 (31) 12 (55) 0.06
n.d. 1 4
KIT + 19 (59) 12 (60)
- 13 (41) 8 (40) n.s.
n.d. 1 6
n.d., not determined; n.s., not significant. Numbers in parentheses are percentages.Breast Cancer Research    Vol 9 No 2    Vincent-Salomon et al.
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Common regions of gains and losses were observed on chro-
mosomes 1q, 8q and Xq in both groups.
We performed a genome-wide comparison of the mean ratios
between the MBC and BLC groups. Comparison of the two
groups was performed, BAC locus by BAC locus, with a
Welch T test. This test identified only four differential BAC loci
between the two groups, three of them located in chromo-
some 10 and one in chromosome 12. Only two of the BAC loci
of chromosome 10 (coordinates on chr10: 6,669,591 to
6,856,917 and 7,349,041 to 7,496,158, respectively) consti-
tuted a contiguous region of gain observed in the MBC group
but not in the BLC group.
With unsupervised clustering (Figure 2), three different clus-
ters were identified: cluster 1 composed of 11 BLCs (85%)
and 2 MBCs (15%), cluster 2 composed of 6 BLCs (40%)
and 9 MBCs (60%), and cluster 3 composed of 9 BLCs
(29%) and 22 MBCs (71%). The differences between these
clusters were statistically significant (p = 0.012). The dendro-
gram of the tumor ratios in order of genomic coordinates (Fig-
ure 2) showed that gain of chromosomes 1q and 8q were
common to all tumors. Chromosomes 4 and 5 showed a com-
mon trend towards loss. Chromosomes 10 and 12 had a dif-
ferent gain profile depending on the tumor cluster (Figure 3):
Table 3
Recurrent identical amplicons observed in at least two tumors
Chromosome Start positiona End positiona Candidate genes Maximum ratio Number of cases
MBC BLC
1q21.2–21.3 148.109 150.70 SNX27, FLG, S100, LRN 2.2 3 0
8p11.21 40.01 42.35 MYST3, ANK1 2.9 3 0
8q24 122.64 128.80 MYC, KIAA0196 2.3 2 2
10p15.3 0.25 1.00 ZMYND11 2.3 3 0
12p13.32–13.33 2.46 4.31 CCND2 2.8 2 0
12p13.2-13.31 5.16 6.37 TNFRSF1A, NTF3, LTBR, CD9 2.7 3 0
12p13.2 7.80 11.7 PRR4, Nanog, CD69, STELLA/DPPA3, PHC1 3.8 3 0
12p13.2 11.95 12.11 ETV6, BCL2L14 9.1 3 0
Xp11.22 51.21 53.95 SSX1, SSX2 2.8 0 2
Xq28 152.66 153.69 MTCP1, TZ, TKTL1, FLNA 2.8 3 1
MBC, medullary breast carcinoma; BLC, basal-like carcinoma. aUCSC Genome Browser on Human May 2004 Assembly; positions are given in 
megabases.
Table 4
Regions of gains and losses, significantly different between the MBC and BLC groups
Chromosome Region Alteration Start position 
(bp)
End position 
(bp)
MBC BLC Median 
frequency 
(percentage)
p
3 3q27 G 159,935,817 163,800,681 G 30.3 0.049
4 4p15.2-15.1 L 27,441,218 30,744,383 L 34.8 0.025
9 9p24 G 628,053 2,280,507 G 30.3 0.0146
9 9p24 G 3,447,196 7,740,086 G 30.3 0.022
9 9p13 G 36,830,822 40,205,823 G 31.8 0.011
10 10p14-13 G 10,572,971 15,532,695 G 53.0 0.018
16 16q24 G 85,913,563 88,552,226 G 25.8 0.01525
X Xq12–13 L 66,582,902 71,458,243 L 38.5 0.001
MBC, medullary breast carcinoma; BLC, basal-like carcinoma; G, gain; L, loss. Start and end coordinates of the regions are indicated in bp (May 
2004 working draft).Available online http://breast-cancer-research.com/content/9/2/R24
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BLC-enriched cluster 1 had a flat profile (around the normal),
and cluster 2 showed a clear gain of distal 10p. The dendro-
gram identified two subgroups in cluster 3: the first subgroup
showed a marked and wide 10p gain profile (cluster 3-1),
while the second subgroup (cluster 3-2) might present a 12p
gain profile. The robustness of this clustering has been con-
firmed by three different multiple resampling approaches: the
first testing the resampling of tumors (consensus clustering
methodology of Monti and colleagues [20]), the second test-
ing the resampling of clones (Multiscale bootstrap methodol-
ogy of Suzuki and colleagues [21]), and a double leave-one-
out methodology developed in the laboratory, testing the resa-
mpling of both tumors and clones (Additional file 3).
A genome-wide comparison of the mean ratios (Welch T test)
between cluster 1 and cluster 3-1 identified three large dis-
criminative regions of gain encompassing chromosome 10p
(Figure 4): the first region was from BAC g11E11 (chr10:
3,723,029 to 3,892,793) to BAC g1int932 (chr10:
14,207,506 to 14,350,672) loci, the second was from BAC
g1int936 (chr10: 15,897,438 to 16,092,470) to BAC
g1int945 (chr10: 22,556,720 to 22,717,956) loci, and the
third was from BAC g1int946 (chr10: 22,559,518 to
22,660,196) to BAC g1int961 (chr10: 24,596,826 to
24,767,011) loci. The second and third regions also differen-
tiated cluster 2 from cluster 3-1 significantly. In contrast, a
comparison of clusters 1 and 3-2 did not identify any discrim-
inative regions on chromosome 12 or other chromosomes.
Although chromosome 12p seemed to be gained in cluster 3-
2 (amplicons excluded), the difference between the two clus-
ters was not statistically significant.
DNA FISH results on MBC and BLC tumors
We chose to assess whether the 10p gains, observed in 53%
of MBCs and discriminant between clusters 1 and 3-1, could
be detected by FISH on frozen tissue sections. For this pur-
pose we analyzed four MBCs tumors with a 10p gain and four
control BLCs without a 10p gain.
In MBCs, the mean aCGH ratio was 1.8 for the TelVysion SG
locus and 1.6 for the g1int 953 locus, for a mean aCGH ratio
of 1.0 for the control locus, g1int978. FISH showed mean
numbers of 2.7 and 2.4 copies per nucleus for the first two
loci, in the presence of 1.6 copies of the g1int978 control
locus.
In BLCs, the mean aCGH ratio was 0.9 for the TelVysion SG
locus, and 1.0 for the g1int 953 locus, for a mean aCGH ratio
of 0.9 for the control locus, g1int978. Mean numbers of 1.1
and 1.0 copies per nucleus were observed by FISH for the first
two loci, in the presence of 1.4 copies of the g1int978 control
locus (Figure 5).
Figure 1
Average genome-wide copy number profiles for medullary breast carcinoma (MBC) and basal-like carcinoma (BLC) tumors Average genome-wide copy number profiles for medullary breast carcinoma (MBC) and basal-like carcinoma (BLC) tumors. Common alterations 
observed in both the MBC (a) and BLC (b) groups are gains of 1q, 8q and Xq (black arrows). The most frequent specific alteration of MBCs (10p 
gains) is indicated by a red arrow. Ordinates: loci ratios, abscissa: order of the loci on chromosomes from 1 to Y.Breast Cancer Research    Vol 9 No 2    Vincent-Salomon et al.
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Discussion
Expression profile analyses [2-4] have categorized invasive
breast carcinomas into five groups: luminal A and B, ERBB2+/
ER-, basal-like and normal breast tumors. The basal-like group
was subsequently defined, using immunohistochemistry, as
being ER- PR- ERBB2-, with tumor cells expressing at least one
basal-myoepithelial marker such as KRT 5/6 or KRT 14 in
association with EGFR or KIT [6,8,22]. Although some BLCs
are associated with a favorable outcome [23,24], most tumors
with a basal-like immunophenotype have been recognized to
be associated with a poor prognosis [5,6,8]. MBCs have
recently been shown to share the basal-like immunophenotype
[9], and some morphological traits that have been reported to
be specific for BLC with poor prognosis, such as tumor necro-
sis, a pushing border of invasion, and a stromal lymphocytic
infiltrate [22,25], are also observed in MBCs. These
phenotypic and immunophenotypic similarities suggest that
these two entities have a common biology despite the fact that
MBC presents a more favorable outcome [11,12]. In the
present study we wished to define the possible phenotypic
and genetic differences between MBCs and BLCs with a view
Figure 2
Dendro-heatmaps of the unsupervised clustering by tumors Dendro-heatmaps of the unsupervised clustering by tumors. The standardized copy number log ratio of all autosomal chromosome loci is shown 
according to a color scale (top). Tumor groups are distinguished with a color code at the bottom of the dendrogram: red, basal-like carcinomas; 
blue, medullary breast carcinomas.Available online http://breast-cancer-research.com/content/9/2/R24
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to understanding the major differences in clinical outcome
between these tumors.
Subtle morphological differences between BLCs and MBCs
suggest that MBCs could be associated with a specific
biology such as the low expression of smooth muscle α-actin
Figure 3
Dendro-heatmaps of chromosomes 10 and 12 Dendro-heatmaps of chromosomes 10 and 12. Cluster 3-1 shows a more marked gain of the 10p region than in the other clusters. Tumor groups 
are distinguished with a color code at the bottom of the dendrogram: red, basal-like carcinomas; blue, medullary breast carcinomas.Breast Cancer Research    Vol 9 No 2    Vincent-Salomon et al.
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in MBCs, corroborating the absence of myofibroblasts in MBC
stroma [10]. In our study, we confirmed that MBCs shared
some basal-like immunophenotypic features and are ER- PR-
ERBB2- tumors but have some specificities such as a more
frequent KRT5/6 staining of the cells than in BLCs. Abd El-
Rehim and colleagues also previously observed [8] that MBCs
expressed KRT 5/6 but not KRT 14. Tot [26] and Jacquemier
and colleagues [9] found lower rates of KRT5/6 positivity
(25% and 44.7%, respectively) than in the present study, but
Tot used a different antibody from that used in the present
study and, in contrast with the present study, Jacquemier and
colleagues included medullary carcinomas that were ER posi-
tive and PR positive in 10.5% and 51.3% of cases, respec-
tively. These differences could explain the higher rates of
KRT5/6 staining observed in our series of MBCs than in pre-
viously published reports.
We also observed high rates of TP53 mutation in the MBC
and BLC groups (77% and 83%, respectively). These rates
are in agreement with previously reported results for MBCs
and BLCs [3,7].
In terms of genetic changes, as described previously by Chin
and colleagues [27], in this basal-like spectrum of tumors we
found low-level copy-number alterations and infrequent high-
level recurrent amplifications. In addition, MBCs seemed to
harbor more gains and losses than BLCs. As seven BLCs
tumors were of grade II and all MBCs were of grade III, we
could not exclude the possibility that this genomic difference
could be simply related to grade. However, five of the seven
grade II BLCs had a mutation in TP53.
As part of the common basal-like spectrum genomic signature,
we found that chromosome 8q, including the 8q24 MYC
region, was frequently gained in MBCs and in BLCs. This
result is in agreement with most published data demonstrating
that breast carcinomas with MYC amplifications were more
frequently ER negative [28] or of the medullary type [29]. It has
also been reported that MYC amplification occurs in younger
patients [30]. The same tendency was observed in our MBC
series (53.5 years in MBCs compared with 60.0 years in
BLCs). Moreover, it has also been shown that MYC contrib-
utes to tumor progression in BRCA1-associated breast can-
cers and that it was gained or amplified in 53% of cases [31].
In agreement with these data, 3 of the 20 patients with MBC
(15%), in whom it was studied, presented a BRCA1 mutation
(data not shown), which is a higher rate than expected (less
than 5%). Taken together, these data suggest that MBC onco-
genesis, as part of the basal-like spectrum, could occur more
frequently in a context of genetic predisposition than other
breast carcinoma types.
Our results suggest that, of the recurrent alterations described
for  BRCA1-associated and high-grade carcinomas, some
Figure 4
Box plot of the bacterial artificial chromosome (BAC) loci in chromosome 10 Box plot of the bacterial artificial chromosome (BAC) loci in chromosome 10. The results of the statistical comparison of the mean of ratios between 
clusters 1 and 3-1 are shown. On this figure, the BAC loci that are significantly different between the two clusters by the Welch T test (p ≤ 0.05, 
Benjamini–Hochberg corrected for genome-wide multiple test) and that lie outside the calculated fold range in at least one cluster are shown in dif-
ferent colors: red, cluster 1; blue, cluster 3-1. The BAC loci that are not significantly different in terms of p value and fold range are shown in grey 
and white, for cluster 1 and cluster 3-1, respectively. The position of the centromere is shown with a vertical pink dashed line.Available online http://breast-cancer-research.com/content/9/2/R24
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could be specific for the basal-like spectrum of tumors
[23,27,32-34].
In addition, we report the existence of a combination of genetic
alterations associated with the MBC phenotype, namely gains
of 3q, 9p, 10p and 16q, losses of 4p, and amplicons of 1q, 8p,
10p and 12p. These data document the heterogeneity of the
basal-like group of tumors and contribute to the understanding
of its carcinogenesis. If confirmed, these alterations would be
helpful in improving the relatively poor diagnostic reproducibil-
ity for MBCs [35].
Some putative candidate genes linked with oncogenesis, such
as  ZMYND11  (BS69),  GATA3,  CCND2,  TNFRSF1A  and
BCL2L14, are present within the two amplicons observed in
10p and 12p. These observations are in agreement with a
recent MBC gene expression profile study that showed a gene
signature specific for MBCs, with genes from the 12p13
region involved in the same pathways [10].
Previous genetic studies have shown that MBCs, like the
basal-like tumor spectrum [27] demonstrated a high rate of
chromosome imbalances [36] rather than recurrent high-level
amplification. This preferential mechanism of oncogenesis has
already been described in predisposition-related cancer syn-
dromes [37]. Our study demonstrates that MBCs effectively
presented a high number of gains and losses, suggesting a
putative alteration within a DNA damage repair process. If con-
firmed, this hypothesis could lead to an explanation of their
higher sensitivity to radiation therapy and their favorable local
and regional outcome [11,12]. These features have already
been reported for BRCA1/2-related tumors [37,38]. It will
therefore be extremely interesting in the future to compare the
aCGH profiles of our MBCs with those of BRCA1-associated
carcinomas. It has also been described previously that an
upregulation of cyclin E induces a chromosome instability
[39]. Cyclin E overexpression described in MBCs [40] and
BRCA1-associated tumors [41] could therefore participate in
the high chromosomal instability of these tumors.
We also observed that losses in Xq were significantly more
frequent in BLCs than in MBCs. These findings are in line with
previous publications showing that BLCs display chromo-
some X abnormalities [42]. Further studies must be con-
ducted to analyze whether the genes involved in the X
chromosome alterations correspond to genes from the active
or inactive X chromosome.
Conclusion
We have refined in depth the molecular characteristics of
MBCs. MBCs tumors belong to the ER- PR- ERBB2- group,
harboring a basal-like immunophenotype with a higher rate of
KRT 5/6 positivity than BLCs. Furthermore, MBCs have
genetic alterations in common with BLCs, such as frequent
TP53 mutations, 8q gains or amplification, 1q gains or ampli-
cons, and X amplicons. Nevertheless, we observed that, in
addition to a large number of chromosomal alterations, MBCs
are characterized by more frequent 10p, 9p, 3q and 16q
gains, 4p losses, and 1q, 8p, and 10p and 12p amplicons.
Taken together, these data demonstrate that MBCs, although
belonging to the spectrum of basal-like tumors, are associated
with specific alterations. A better knowledge of the heteroge-
neity of the basal-like tumor group should be useful in the near
future for more appropriate patient management. Furthermore,
Figure 5
Confirmation of 10p gains with the use of fluorescence in situ hybridization (FISH) Confirmation of 10p gains with the use of fluorescence in situ hybridization (FISH). FISH analysis of cases 33 (medullary breast carcinoma) and 26 
(basal-like carcinoma) with TelVysion SG 10p (probe 1) shown in green, g1int953 in red (probe 2), and control probe g1int978 in yellow (probe 3).Breast Cancer Research    Vol 9 No 2    Vincent-Salomon et al.
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the new regions that we have defined as being characteristi-
cally modified in MBCs should provide insight into the onco-
genic features of this particular class of tumors.
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